Biogen Idec Makes A Case For Neurology
This article was originally published in The Pink Sheet Daily
Management laid out Biogen's neurology pipeline to investors Nov. 30, but most of the drugs are in early development.
You may also be interested in...
The non-profit research organization, focused on the development of drugs for the treatment of ALS, is making clinical progress on two drugs, one of which is Novartis’ Gilenya.
Saying his new company is spread "a mile wide and an inch deep," Biogen Idec Inc.'s CEO George Scangos, PhD, affirmed Nov. 3 that the big biotech firm will drastically pare its pipeline, cut 13% of staff, and refocus its efforts around its historic strength – its multiple sclerosis franchise.
UCB gains rights to Synosia's potential Parkinson's disease therapies in deal that could be worth $725 million in milestones